CG Oncology, Inc.CGONEarnings & Financial Report
Nasdaq
NextMar 30, 2026
CGON Q3 2025 Key Financial Metrics
Revenue
$1.7M
Gross Profit
N/A
Operating Profit
$-51.1M
Net Profit
$-43.8M
Gross Margin
N/A
Operating Margin
-3069.0%
Net Margin
-2629.5%
YoY Growth
3774.4%
EPS
$-0.57
Financial Flow
CG Oncology, Inc. Q3 2025 Financial Summary
CG Oncology, Inc. reported revenue of $1.7M for Q3 2025, with a net profit of $-43.8M (-2629.5% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $1.7M |
|---|---|
| Net Profit | $-43.8M |
| Gross Margin | N/A |
| Operating Margin | -3069.0% |
| Report Period | Q3 2025 |
CG Oncology, Inc. Annual Revenue by Year
CG Oncology, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.1M).
| Year | Annual Revenue |
|---|---|
| 2024 | $1.1M |
| 2023 | $204.0K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1000 | $529000 | $111000 | $43000 | $456000 | $52000 | $0 | $1.7M |
| YoY Growth | N/A | 172.7% | N/A | 377.8% | 45500.0% | -90.2% | N/A | 3774.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $199.3M | $579.1M | $564.3M | $552.5M | $754.8M | $728.2M | $701.4M | $729.9M |
| Liabilities | $14.5M | $10.2M | $12.0M | $15.7M | $21.4M | $23.4M | $31.1M | $42.3M |
| Equity | $-123.1M | $568.9M | $552.4M | $536.8M | $733.4M | $704.8M | $670.4M | $687.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-26.0M | $-16.1M | $-15.9M | $-20.7M | $-29.3M | $-28.0M | $-38.9M |